Targeting RAC1 in glioblastoma: prognostic value, immune landscape, and small molecule therapeutic potential - Top-Institutions - MDSpire

Targeting RAC1 in glioblastoma: prognostic value, immune landscape, and small molecule therapeutic potential

  • By

  • Qionghui Wu

  • Shanlin Chen

  • Xiaodong Xie

  • Xinli Feng

  • Zhenchang Zhang

  • Gang Su

  • June 18, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Neuro-Oncology

  • #2

    UCSF Helen Diller Family Comprehensive Cancer Center
    UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

    Key Differentiators

    • Oncology
    • Neuro-Oncology

  • #3

    Dana-Farber Cancer Center
    Dana-Farber Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Neuro-Oncology

  • #4

    Northwestern University
    Northwestern University

    Chicago, Illinois

    Key Differentiators

    • Oncology
    • Neuro-Oncology

  • #5

    Columbia University Medical Center
    Columbia University Medical Center

    New York, New York

    Key Differentiators

    • Oncology
    • Neuro-Oncology

Original Source(s)

Targeting RAC1 in glioblastoma: prognostic value, immune landscape, and small molecule therapeutic potential

  • by Qionghui Wu, Shanlin Chen, Xiaodong Xie, Xinli Feng, Zhenchang Zhang, Gang Su

  • June 18, 2026

Related Content

The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells

Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance

Conversion-oriented multimodal therapy enabling definitive surgery in a patient with FIGO stage IVA cervical cancer at high risk of fistula formation: a case report